FDA Experts Endorse Pioneering New Gene Therapy Treatment For Blindness

Wochit Headline News - Friday, 13 October 2017  (1 week ago)
A new ground-breaking gene therapy from Spark Therapeutics took a huge step towards FDA approval yesterday as a panel of experts offered their support for getting the treatment into the market. The vote was 16 to 0 favoring the benefit-risk profile of the drug, providing a compelling reason for the US FDA to approve the first US vector-delivered gene therapy.

Recent related news

A potentially groundbreaking treatment for a rare form of blindness moved one step closer to U.S. approval Thursday, as federal health advisers endorsed the...
1 week ago • WorldNews
Spark Therapeutics Inc. (NASDAQ:ONCE) shares surged in premarket trade after a U.S. Food and Drugs Administration advisory committee recommended approval of its...
1 week ago • Proactive Investors
A gene therapy treatment called Luxturna has already improved the eyesight of people suffering from a genetic disorder in testing. Today, the US Food and Drug...
1 week ago • Futurism
(Reuters) - U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc's Kite Pharma, marking the...
1 day ago • Reuters

You might like